Skip to main content
. Author manuscript; available in PMC: 2014 Oct 29.
Published in final edited form as: Cochrane Database Syst Rev. 2004;(1):CD001884. doi: 10.1002/14651858.CD001884.pub2
Methods Methods of randomisation and allocation concealment were not described
Participants 40 consecutive male patients undergoing elective primary myocardial revascularisation were randomly assigned to one of two groups

  1. Desmopressin (DDAVP) group: n = 19; mean age (+/−SD) = 56 (9) years.

  2. Placebo group: n = 20; mean age (+/−SD) = 58 (8) years.


NB: Gender data not reported. One patient was excluded from the desmopressin group due to excessive post-operative bleeding requiring re-exploration - surgical cause identified
Interventions

  1. DDAVP group received 0.3 ug/kg of DDAVP IV after the termination of cardiopulmonary bypass (CPB) and 5 minutes after protamine administration for the reversal of heparin.

  2. Placebo group received an equivalent amount of IV saline over 15 minutes.


NB: Both groups were exposed to cell salvage.
Outcomes Number of patients transfused allogeneic blood (n)Amount of allogeneic blood transfused (units)
Number of patients transfused platelets (n)
Blood loss (ml)
Re-operation for bleeding (n)
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Method of randomisation was not described.
Allocation concealment? Unclear B - Unclear
Blinding?
All outcomes		 Yes Double blind.